0000000000123757

AUTHOR

Roser Torra

showing 2 related works from this author

Additional file 1 of Cardiovascular risk factors and the impact on prognosis in patients with chronic kidney disease secondary to autosomal dominant …

2021

Additional file 1.

Data_FILES
researchProduct

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data

2009

Summary Background We analysed 5-year treatment with agalsidase alfa enzyme replacement therapy in patients with Fabry's disease who were enrolled in the Fabry Outcome Survey observational database (FOS). Methods Baseline and 5-year data were available for up to 181 adults (126 men) in FOS. Serial data for cardiac mass and function, renal function, pain, and quality of life were assessed. Safety and sensitivity analyses were done in patients with baseline and at least one relevant follow-up measurement during the 5 years (n=555 and n=475, respectively). Findings In patients with baseline cardiac hypertrophy, treatment resulted in a sustained reduction in left ventricular mass (LVM) index af…

AdultMalemedicine.medical_specialtyUrologyRenal functionKidney Function TestsMuscle hypertrophyQuality of lifeSurveys and QuestionnairesEpidemiologymedicineHumansRegistriesPain MeasurementVascular diseasebusiness.industryGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry's diseaseFabry diseaseRecombinant ProteinsSurgeryIsoenzymesTreatment Outcomealpha-GalactosidaseHeart Function TestsQuality of LifeFabry DiseaseFemalebusinessThe Lancet
researchProduct